Promising ovarian cancer research
October 20, 2014
In the News: The treatment of women with ovarian cancer is poised for a significant transformation, propelled by a surge in clinical trials of four main groups of therapies, according to a recent article in OncLive, published by the Oncology Specialty Group.
The site asked Dr. Krishnansu S. Tewari, associate professor of gynecologic oncology, former UC Irvine researcher Dr. Bradley J. Monk, and other experts to provide further perspectives on this evolving field.
PARP inhibitors, vaccines, anti-PD-1/PD-L1 therapies and anti-angiogenic therapies are changing the landscape in the treatment of ovarian cancer. In particular, the angiogenesis inhibitor bevacizumab generated a lot of interest.
The OncLive article cited a clinical trial conducted by Tewari involving the PD-1 inhibitor nivolumab. Based on “promising clinical efficacy” results," a larger study is being formed to “look specifically at 3-mg/kg nivolumab in advanced ovarian cancer.”
See the article, “Promising Treatments on Horizon in Ovarian Cancer” ›
Learn more about Monk, Tewari and Overcoming Ovarian Cancer ›
